Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coal tar

This article was originally published in The Tan Sheet

Executive Summary

FDA finds "no adequate basis to change the status of coal tar-containing drug products for the treatment of dandruff, seborrheic dermatitis and psoriasis from OTC to prescription or to require additional warning statements on product labeling," agency says in Feb. 22 response to Occupational Knowledge International's citizen petition seeking Rx-only sales of the ingredient. California Prop 65 litigation had been stayed pending FDA's determination

You may also be interested in...

OTC Coal Tar Skin Cancer Causation Data Lacking - FDA

The future of California Proposition 65 litigation against manufacturers, distributors and retailers of coal tar-containing dandruff shampoos, soaps and ointments could become clearer at a March 16 status conference in San Francisco state court.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts